HIGHLIGHTS
- who: Ai Irisawa from the Department Pharmaceutical University have published the article: Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer, in the Journal: Scientific Reports Scientific Reports
- what: The highest grade of toxicity during the study period was used for the analysis. The authors retrospectively evaluated the incidence of FN and severe neutropenia associated with mFOLFIRINOX therapy, to identify the risk factors for severe neutropenia. The patient selection criteria for this study were broader than those of previous Japanese phase II studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.